Current, New and Future Therapeutic Targets in Inflammatory Bowel Disease: A Systematic Review.

Abstract:

:Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are chronic relapsing conditions resulting from immune system activity in a genetically predisposed individual. IBD is based on progressive damage to the inflamed gut tissue. As its pathogenesis remains unknown, recent accumulating data have demonstrated that IBD is a complex and multi-factorial disorder correlated with host luminal factors, which lead to an imbalance between pro- and anti-inflammatory signaling. The growing understanding of the molecular mechanisms responsible for IBD has suggested a wide range of potential therapeutic targets to treat this condition. Some patients do not have a satisfactory response to current therapeutic medications such as antitumor necrosis factor (TNF) agents, or their response decreases over time. As a result, IBD therapeutics have been changed recently, with several new agents being evaluated. The identification of various inflammatory cascades has led to forming the idea to have novel medications developed. Medications targeting Janus kinases (JAK), leukocyte trafficking Interleukin (IL) 12/23, and Sphingosine 1 phosphate (S1P) are among these newly developed medications and highlight the role of microbial-host interaction in inflammation as a safe promising strategy. This systematic review aims to summarize different molecular targeting therapeutics, the most potent candidates for IBD treatment in recent studies.

journal_name

Curr Pharm Des

authors

Alimohammadi N,Koosha F,Rafeian-Kopaei M

doi

10.2174/1381612826666200406081920

subject

Has Abstract

pub_date

2020-01-01 00:00:00

pages

2668-2675

issue

22

eissn

1381-6128

issn

1873-4286

pii

CPD-EPUB-105657

journal_volume

26

pub_type

杂志文章
  • Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia.

    abstract::There is growing evidence for the involvement of glutamatergic abnormalities in schizophrenia. Uncompetitive NMDA receptor (NMDAR) antagonists induce effects closely resembling both the positive and negative symptoms of schizophrenia; candidate risk genes for schizophrenia converge on the NMDAR expressing synapse; and...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161209788957438

    authors: Stone JM

    更新日期:2009-01-01 00:00:00

  • The role of hyperglycaemia and the hypercoagulable state in the pathogenesis of cardiovascular events in diabetes mellitus: implications for hypertension management.

    abstract::Population studies have identified diabetes mellitus as a risk factor for cardiac and vascular events, with a common association with hypertension. Observational studies have consistently demonstrated blood glucose as a continuous cardiovascular risk factor. Experimental studies suggest that elevated blood glucose, th...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161206776843322

    authors: Lim HS,MacFadyen RJ,Bakris G,Lip GY

    更新日期:2006-01-01 00:00:00

  • Vesicular carriers for skin drug delivery: the Pheroid™ technology.

    abstract::The skin remains an attractive area for drug delivery. The skin, however, often limits the ingress of drugs, because of its very low permeability. Much research, focusing on employing a variety of physical and chemical methods, aimed at reversibly altering skin permeability in favour of compounds, has been reported. O...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612821666150428125812

    authors: Kilian D,Shahzad Y,Fox L,Gerber M,Du Plessis J

    更新日期:2015-01-01 00:00:00

  • A leap into the chemical space of protein-protein interaction inhibitors.

    abstract::Protein-protein interactions (PPI) are involved in vital cellular processes and are therefore associated to a growing number of diseases. But working with them as therapeutic targets comes with some major hurdles that require substantial mutations from our way to design drugs on historical targets such as enzymes and ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161212802651571

    authors: Villoutreix BO,Labbé CM,Lagorce D,Laconde G,Sperandio O

    更新日期:2012-01-01 00:00:00

  • Drug combinations for dyslipidemia and obesity treatment in metabolic syndrome.

    abstract::Metabolic syndrome (MetS) is a cluster of risk factors, each one individually associated with increased cardiovascular disease risk. Treatment of all components of MetS is expected to result in reduced risk. Treatment of MetS mainly includes lifestyle changes. In addition, drug therapy may be considered, especially co...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161209789105054

    authors: Florentin M,Elisaf MS,Mikhailidis DP,Liberopoulos EN

    更新日期:2009-01-01 00:00:00

  • Metal/Metal Oxide Nanoparticles: Toxicity, Applications, and Future Prospects.

    abstract::The ever-growing resistance of pathogens to antibiotics and crop disease due to pest has triggered severe health concerns in recent years. Consequently, there is a need of powerful and protective materials for the eradication of diseases. Metal/metal oxide nanoparticles (M/MO NPs) are powerful agents due to their ther...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612825666191111091326

    authors: Chaudhary RG,Bhusari GS,Tiple AD,Rai AR,Somkuvar SR,Potbhare AK,Lambat TL,Ingle PP,Abdala AA

    更新日期:2019-01-01 00:00:00

  • Mechanisms of corticosteroid resistance in severe asthma and chronic obstructive pulmonary disease (COPD).

    abstract::Inhaled glucocorticoids, also know as corticosteroids (ICS), revolutionized the treatment of asthma by suppressing airways inflammation and ICS therapy now forms the basis of treatment of asthma of all severities. More recently and usually in combination with a long-acting β-agonist (LABA), ICS use has been establishe...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章

    doi:10.2174/138161210793797889

    authors: Adcock IM,Marwick J,Casolari P,Contoli M,Chung KF,Kirkham P,Papi A,Caramori G

    更新日期:2010-01-01 00:00:00

  • Targeting RANK/RANKL in the treatment of solid tumours and myeloma.

    abstract::Cancers which damage the human skeleton include multiple myeloma, where the primary tumour colonises bone directly, or breast and prostate cancer, where malignant cells travel from the primary tumour to form clonal outgrowths within the bone. Owing to the interaction of tumour cells with those normally found in the bo...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161210791034021

    authors: Buckle CH,Neville-Webbe HL,Croucher PI,Lawson MA

    更新日期:2010-01-01 00:00:00

  • Contribution of Nanotechnology to Improved Treatment of Periodontal Disease.

    abstract::Periodontal disease is chronic inflammation of periodontal tissues resulting in formation of periodontal pockets, periodontal attachment loss and progressive destruction of the ligament and alveolar bone. This review gives an update on periodontal disease pathogenesis, which is important for the development of novel m...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612821666150531171829

    authors: Zupancic S,Kocbek P,Baumgartner S,Kristl J

    更新日期:2015-01-01 00:00:00

  • Ocular involvement in fetal alcohol spectrum disorder: a review.

    abstract::Fetal Alcohol Syndrome (FAS), the most severe manifestation of Fetal Alcohol Spectrum Disorder (FASD) is considered the leading non-hereditary cause of mental retardation and neurological deficit in the Western world. There lie a huge associated human cost to both FASD victims and their families and a considerable fin...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612820666140205144114

    authors: Brennan D,Giles S

    更新日期:2014-01-01 00:00:00

  • New perspectives in glioma immunotherapy.

    abstract::Glioblastoma (GBM) is a deadly tumor, which in spite of surgery and radio/chemotherapy frequently undergoes relapses related to the infiltration of the normal parenchyma and to resistance to cytotoxic and radiation therapy. Immunotherapy may represent a promising approach, which may complement existing therapies with ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161211797249206

    authors: Daga A,Bottino C,Castriconi R,Gangemi R,Ferrini S

    更新日期:2011-01-01 00:00:00

  • Machine Learning Methods in Precision Medicine Targeting Epigenetic Diseases.

    abstract:BACKGROUND:On a tide of big data, machine learning is coming to its day. Referring to huge amounts of epigenetic data coming from biological experiments and clinic, machine learning can help in detecting epigenetic features in genome, finding correlations between phenotypes and modifications in histone or genes, accele...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612824666181112114228

    authors: Fan S,Chen Y,Luo C,Meng F

    更新日期:2018-01-01 00:00:00

  • Recent Advances in Neuroinflammation Therapeutics: PPARs/LXR as Neuroinflammatory Modulators.

    abstract::Neurodegenerative disorders are one of the most critical public health concerns of our times. Regrettably, therapeutic interventions currently available have shown only partial benefits to patients affected by one of these disorders. Although the important advances made during the last decades, several questions regar...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612822666151223103038

    authors: Bastias-Candia S,Garrido A N,Zolezzi JM,Inestrosa NC

    更新日期:2016-01-01 00:00:00

  • Anti-TNF therapy for Crohn's disease.

    abstract::Although the cause of Crohn's disease remains unknown considerable progress has been made in recent years to unravel the pathogenesis of the inflammatory processes seen in chronic idiopathic inflammatory bowel diseases (IBD). Th-1 lymphocytes seem to orchestrate the inflammation through the production of pro-inflammat...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612033391982

    authors: D'Haens G

    更新日期:2003-01-01 00:00:00

  • Current and future clinical strategies in colon cancer prevention and the emerging role of chemoprevention.

    abstract::In the third millennium preventive medicine is becoming a corner stone in our concept of health. Colorectal cancer (CRC) fits the criteria of a disease suitable for prevention interventions. It is a prevalent disease that is associated with considerable mortality and morbidity rates, with more than 1,000,000 new cases...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161207781368783

    authors: Boursi B,Arber N

    更新日期:2007-01-01 00:00:00

  • High-density lipoprotein-mediated anti-atherosclerotic and endothelial-protective effects: a potential novel therapeutic target in cardiovascular disease.

    abstract::Reduced levels of high-density lipoprotein cholesterol (HDL) are associated with a substantially increased risk of coronary disease and cardiovascular events. Furthermore, numerous studies have suggested that HDL may exert several potentially important antiatherosclerotic and endothelial-protective effects. In particu...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161210791051013

    authors: Besler C,Heinrich K,Riwanto M,Lüscher TF,Landmesser U

    更新日期:2010-05-01 00:00:00

  • Improving the targeting of tubulin-binding agents: lessons from drug resistance studies.

    abstract::Natural product drugs that target the tubulin/microtubule system remain an important component in the therapeutic arsenal to treat many types of malignancies. Agents such as the taxanes and vinca alkaloids bind to beta-tubulin and disrupt microtubule dynamics by inducing a potent mitotic block and subsequent cell deat...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612053764706

    authors: Verrills NM,Kavallaris M

    更新日期:2005-01-01 00:00:00

  • The role of protonation states in ligand-receptor recognition and binding.

    abstract::In this review we discuss the role of protonation states in receptor-ligand interactions, providing experimental evidences and computational predictions that complex formation may involve titratable groups with unusual pKa's and that protonation states frequently change from unbound to bound states. These protonation ...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612811319230004

    authors: Petukh M,Stefl S,Alexov E

    更新日期:2013-01-01 00:00:00

  • The role of polyunsaturated fatty acids (PUFA) in the treatment of dyslipidemias.

    abstract::Polyunsaturated fatty acids (PUFA) are a family of lipids including some subgroups identified by the position of the last double bond in their structure. PUFA n-3 include alpha linolenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), while PUFA n-6 include linoleic acid (LA) and arachidonic a...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章

    doi:10.2174/138161209789909773

    authors: Zuliani G,Galvani M,Leitersdorf E,Volpato S,Cavalieri M,Fellin R

    更新日期:2009-01-01 00:00:00

  • The "Neurocentric" Approach to Essential Hypertension: How Reliable is the Paradigm of Hyperkinetic Hypertension? A Focus on the Sympathetic Nervous System Dysregulation in Essential Hypertensive Patients with Elevated Resting Heart Rate.

    abstract:BACKGROUND:Clinic resting heart rate (RHR), is one of the cardiovascular parameters more easily measurable. In the general population RHR has been associated with total and cardiovascular mortality and higher rate of vascular events. OBJECTIVE:The case of essential hypertension is in some ways peculiar: in the past de...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612823666170911102711

    authors: Di Raimondo D,Musiari G,Grova M,Miceli G,Tuttolomondo A,Pinto A

    更新日期:2017-01-01 00:00:00

  • Effects of High Intensity Statin Therapy in the Treatment of Diabetic Dyslipidemia in Patients with Coronary Artery Disease.

    abstract:BACKGROUND:Diabetic dyslipidemia has specifics that differ from dyslipidemia in patients without diabetes, which contributes to accelerated atherosclerosis equally as dysglycemia. The aim of this study was to deduce the interdependence of diabetic dyslipidemia and cardiovascular diseases (CVD), therapeutic strategies a...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612824666171227215708

    authors: Vavlukis M,Kedev S

    更新日期:2018-01-01 00:00:00

  • Risk Factors for Myocardial Infarction in Women and Men: A Review of the Current Literature.

    abstract:BACKGROUND:Cardiovascular disease has been the leading cause of death in both sexes in developed countries for decades. In general, men and women share the same cardiovascular risk factors. However, in recent trials including both men and women sexspecific analyses have raised awareness of sex differences in cardiovasc...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612822666160309115318

    authors: Pedersen LR,Frestad D,Michelsen MM,Mygind ND,Rasmusen H,Suhrs HE,Prescott E

    更新日期:2016-01-01 00:00:00

  • Impact of Electrostatics on Processing and Product Performance of Pharmaceutical Solids.

    abstract::Manufacturing of pharmaceutical solids involves different unit operations and processing steps such as powder blending, fluidization, sieving, powder coating, pneumatic conveying and spray drying. During these operations, particles come in contact with other particles, different metallic, glass or polymer surfaces and...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612821666151008124811

    authors: Desai PM,Tan BM,Liew CV,Chan LW,Heng PW

    更新日期:2015-01-01 00:00:00

  • Toward a design of affordable, topical microbicides: acylcarnitine analogues.

    abstract::Most heterosexual women want to reduce the risk of acquiring a sexually transmitted infection; many also want to control their fertility. Several chemical agents have been proposed to dramatically slow the spread of HIV infections. Ideally, vaginal microbicides, with or without contraceptive properties, should be safe...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161205774580705

    authors: Gandour RD

    更新日期:2005-01-01 00:00:00

  • Ras signaling pathway proteins as therapeutic targets.

    abstract::Ras is a 21 kDa membrane-localized G protein that is coupled to receptor and non-receptor tyrosine kinase activation of downstream cytoplasmic and nuclear events. Mutated ras genes are common, and occur in a wide variety of human malignancies. These activating mutations result in constitutive signaling, thereby stimul...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612013397258

    authors: Adjei AA

    更新日期:2001-11-01 00:00:00

  • Hypersensitivity reactions to neuromuscular blocking agents.

    abstract::Neuromuscular blocking agents are the leading drugs responsible for immediate hypersensitivity reactions during anaesthesia. Most hypersensitivity reactions represent IgE-mediated allergic reactions. Their incidence is estimated to be between 1 in 3,000 to 1 in 110,000 general anaesthetics. However striking variations...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161208786369704

    authors: Mertes PM,Aimone-Gastin I,Guéant-Rodriguez RM,Mouton-Faivre C,Audibert G,O'Brien J,Frendt D,Brezeanu M,Bouaziz H,Guéant JL

    更新日期:2008-01-01 00:00:00

  • Peripheral Corticotropin Releasing Factor Signaling Inhibits Gastric Emptying: Mechanisms of Action and Role in Stress-related Gastric Alterations of Motor Function.

    abstract::The activation of Corticotrophin Releasing-Factor (CRF) receptors in the brain is well established to coordinate the endocrine, behavioral, autonomic and visceral responses to stress. In addition, CRF receptors are also expressed within the gut where they exert biological actions and play a role in modulating stress-r...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612823666170228142428

    authors: Czimmer J,Tache Y

    更新日期:2017-01-01 00:00:00

  • Receptor binding ligands to image infection.

    abstract::The current gold standard for imaging infection is radiolabeled white blood cells. For reasons of safety, simplicity and cost, it would be desirable to have a receptor-specific ligand that could be used for imaging infection and that would allow a differential diagnosis between sterile and septic inflammatory processe...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161208786549416

    authors: Chianelli M,Boerman OC,Malviya G,Galli F,Oyen WJ,Signore A

    更新日期:2008-01-01 00:00:00

  • Novel approaches in the treatment of angiogenic eye disease.

    abstract::Angiogenic eye disease is among the most common causes of blindness worldwide. Current treatment approaches are insufficiently effective and partially associated with significant adverse effects. From an investigational view, the eye provides an ideal setting to observe real-time and serial observations of angiogenesi...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/1381612054367292

    authors: Wegewitz U,Göhring I,Spranger J

    更新日期:2005-01-01 00:00:00

  • Intestinal immunomodulation. Role of regulative peptides and promising pharmacological activities.

    abstract::About 50 peptides, and a similar number of peptide receptors, are known to be present in the gut and this amount is likely to rise significantly over the next few years. While there has been a massive research effort to define their functions and their anatomical distribution in the central nervous system (CNS), the u...

    journal_title:Current pharmaceutical design

    pub_type: 杂志文章,评审

    doi:10.2174/138161208783330745

    authors: Motilva V,Talero E,Calvo JR,Villegas I,Alarcón-de-la-Lastra C,Sánchez-Fidalgo S

    更新日期:2008-01-01 00:00:00